Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Amphstar Pharmaceuticals, Inc. (AMPH) · oqro.io/stocks/AMPH · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Amphstar Pharmaceuticals, Inc. insider trading
Have Amphstar Pharmaceuticals, Inc. insiders bought shares recently?
No open-market purchase by an insider of Amphstar Pharmaceuticals, Inc. was filed in the last 90 days. The latest on record was on Aug 14, 2020.
How often do Amphstar Pharmaceuticals, Inc. insiders buy and sell shares?
Since 2014, Amphstar Pharmaceuticals, Inc. insiders reported 10 open-market purchases and 473 sales on Forms 4 and 5, with purchases in 3 different years, most recently 2020.
Who is selling Amphstar Pharmaceuticals, Inc. stock?
In the last 90 days, 2 insiders of Amphstar Pharmaceuticals, Inc. (AMPH) reported 6 open-market sales worth $1.56M in total on SEC Form 4. The largest seller by value was William J Peters, with $1.25M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade AMPH?
No trade in Amphstar Pharmaceuticals, Inc. (AMPH) was disclosed by a member of Congress in the last 12 months.
When does Amphstar Pharmaceuticals, Inc. report its next results?
Amphstar Pharmaceuticals, Inc.'s next results are expected on Feb 24, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
AMPH price and disclosed activity
+11.4% (+$2.89) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $25.36 on Nov 20, 2025 to $28.25 on Nov 20, 2026 (+11.4%). Disclosed in this range: 6 insider trades, 6 pre-arranged insider sales, 0 Congress trades, and 2 13F position changes for 2 quarters ending in it.
$15$20$25$35$28.25
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 12 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceuticals company based in Rancho Cucamonga, California.
Last 12 months
+11.4%
S&P 500 +5.7% over the same dates
Market value
$1.2B
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 4.26M shares sold short (10.0% of shares outstanding), −1.7% vs the previous count, 11.3 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Owners above 5%
No Schedule 13D or 13G filing on AMPH over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Latest results: quarter ending Sep 30, 2026
Revenue
$208M
+8.2% vs the same quarter a year earlier
Free cash flow, last 12 months
$139M
This quarter $33.4M, a year earlier $47.2M
Net debt
$406M
Debt $610M, cash $205M, at Sep 30, 2026
Net income, last 12 months
$99M
Operating profit covers interest 5.25x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
Written by software from the filings listed below · Oct 16, 2026
Insiders. In the 30 days to Oct 16, 2026, insiders filed 0 open-market purchases and 2 open-market sales, about $343K, in 2 filings by 2 people. Amphstar Pharmaceuticals, Inc. on OQRO
3 more points, with the facts they come from, are in OQRO Pro.
after the market closes; the date can move until the company confirms it
Purchases after results
100%
10 of 10 insider purchases since 2014 came within 30 days after a results announcement
From Amphstar Pharmaceuticals, Inc.'s own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Amphstar Pharmaceuticals, Inc.'s policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Insider buying and selling since 2014
Insiders of Amphstar Pharmaceuticals, Inc. reported 10 open-market purchases and 473 sales since 2014; purchases in 3 different years, most recently 2020.
Year
Bought
Sold
2026
—
$1.91M8×8 trades
2025
—
$1.15M14×14 trades
2024
—
$25.8M43×43 trades
2023
—
$18.5M47×47 trades
2022
—
$18.5M57×57 trades
2021
—
$10.2M49×49 trades
2020
$20K1×1 trade
$7.33M39×39 trades
2019
—
$11.1M39×39 trades
2018
$643K2×2 trades
$15.8M52×52 trades
2017
—
$4.73M34×34 trades
2016
—
$16M42×42 trades
2015
—
$15M49×49 trades
2014
$259K7×7 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Amphstar Pharmaceuticals, Inc. filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 12 open-market sales (about $2.39M, in 10 filings, by 4 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 13 open-market sales (about $1.79M, in 12 filings). (Amphstar Pharmaceuticals, Inc. on OQRO)
Funds and stakes. Fund 13F filings recorded in the 12 months show 2 new or larger positions and 0 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. FINRA short interest for AMPH on the settlement date of Oct 30, 2026 was 4,261,462 shares (-1.67% on the previous report), about 11.34 days of average volume. In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: none on record; the largest that shrank: Epoch Investment Partners, Inc. (sold out); Freestone Grove Partners LP (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Amphstar Pharmaceuticals, Inc. filed a Form 8-K on Nov 5, 2026 (Item 2.02) that OQRO classes as: reported its results. Amphstar Pharmaceuticals, Inc. filed a Form 8-K on Jul 13, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
Who holds it. 208 funds reported a stake in Amphstar Pharmaceuticals, Inc. in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (18.4% of the value reported), DIMENSIONAL FUND ADVISORS LP (8.1% of the value reported), STATE STREET CORP (5.8% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Amphstar Pharmaceuticals, Inc. filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 12 open-market sales (about $2.39M, in 10 filings, by 4 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 13 open-market sales (about $1.79M, in 12 filings).
The largest sale: William J Peters, CFO, EVP & TREASURER, about $448K, filed Nov 6, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 2 new or larger positions and 0 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
FINRA short interest for AMPH on the settlement date of Oct 30, 2026 was 4,261,462 shares (-1.67% on the previous report), about 11.34 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: none on record; the largest that shrank: Epoch Investment Partners, Inc. (sold out); Freestone Grove Partners LP (sold out). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $8.31M for its principal executive officer, and an average of $2.96M for the other named executive officers.
Company reports, price and press
Amphstar Pharmaceuticals, Inc. filed a Form 8-K on Nov 5, 2026 (Item 2.02) that OQRO classes as: reported its results.
Amphstar Pharmaceuticals, Inc. filed a Form 8-K on Jul 13, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
Amphstar Pharmaceuticals, Inc. filed a Form 8-K on Mar 6, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
Where the revenue comes from
Latest quarter
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 5, 2026. Quarterly reports are not audited. Read the filing
By region
United States$191M92%
+5.9% on the same quarter a year earlier ($180M)
France$10.6M5.1%
+9.2% on the same quarter a year earlier ($9.68M)
China$6.17M3.0%
+228% on the same quarter a year earlier ($1.88M)
Total revenue$208M+8.2%
Off-exchange trading: 42.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (27.1% on ATS, 15.2% with other brokers), above its 26-week average of 39.9%. Weeks of Sep 21 to Oct 16, 2026.
The company's own opening sentence of that report reads: "On March 3, 2026 (the 'Effective Date'), Amphastar Pharmaceuticals, Inc. ('Amphastar' or, the 'Company'), entered into executive employment agreements with each of Jacob Liawatidewi, the Company’s Executive Vice President of Corp..."
Press coverage listed by Finnhub: "AMPH Q3 2026 deep dive: pipeline progress and manufacturing challenges shape outlook" (Yahoo, Nov 10, 2026).
Press coverage listed by Finnhub: "AMPH Q2 Deep Dive: Portfolio Expansion and Pipeline Progress Drive Results" (Yahoo, Aug 11, 2026).
AMPH closed at $29.71 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $26.14 to $29.71, a change of +13.7%.
Who holds it
208 funds reported a stake in Amphstar Pharmaceuticals, Inc. in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (18.4% of the value reported), DIMENSIONAL FUND ADVISORS LP (8.1% of the value reported), STATE STREET CORP (5.8% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 26, 2026. Read the filing
By region
United States$681M95%
−3.7% on the year before ($708M)
France$35.3M4.9%
+77% on the year before ($19.9M)
China$3.18M0.4%
−27% on the year before ($4.34M)
Total revenue$720M−1.7%
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 6,000 words.
From “Overview”, in the company's words
We are a biopharmaceutical company focusing on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredient, or API products. We currently manufacture and sell over 25 prescription pharmaceutical products, and an over-the-counter product, Primatene MIST®. We are currently developing a portfolio of generic abbreviated new drug applications, or ANDAs, biologics license applications, or BLAs, including biosimilar insulin product candidates, and proprietary product candidates, which are in various stages of development and target a variety of indications. One ANDA and one biosimilar insulin candidate are currently on file with the FDA.
What the section covers (32 headings)
Overview
Macroeconomic Trends and Uncertainties
Recent Developments
Business Segments
Results of Operations
Net revenues
Product Revenues, net
Other Revenues
Backlog
Gross Margins
Selling, distribution, and marketing, and general and administrative
Research and development
Non-operating expenses, net
Income tax provision
And 18 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026 and Form 10-Q filed Nov 5, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: SIGMA X2 (13.1%), UBS ATS (12.0%), MS TRAJECTORY CROSS (ATS-1) (11.9%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Since Nov 19, 2025, AMPH is up 11.4% and the index fund is up 4.1%: 7 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much AMPH moves
A usual day
±1.6%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
4.0%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−23.6%Feb 27, 2026
Largest one-day rise
+7.6%Jun 24, 2026
Deepest fall of the year
−42.6%From the close of Jan 12, 2026 to May 15, 2026.
Days of 5% or more
19Out of 252 sessions, in either direction.
Beta 0.4(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Risk factors in the annual report
Latest annual report filed Feb 26, 2026, compared with the one filed Mar 3, 2025. Read the filing
New risk factors in the latest annual report (1 heading)
Complications with the design or implementation of our new enterprise resource planning system could adversely impact our business and operations.
Legal proceedings (Item 3)
From time to time, we may also be involved in a variety of other claims, lawsuits, investigations, and proceedings related to securities laws, product liability, patent infringement, contract disputes, employment, and other matters that arise in the normal course of our business. In addition, third parties may, from time to time, assert claims against us in the form of letters and other communications.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.